Company news
Tetra Bio-pharma Inc. (OTC:TBPMQ) news
Tetra Bio-pharma Inc. news releases on 6ix. Latest, Feb 20, 2020: Tetra Bio-Pharma Inc. Announces Listing of Warrants
Press releases — page 3
Tetra Bio-Pharma Inc. Announces Listing of Warrants
February 20, 2020
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
February 20, 2020
Tetra Bio-Pharma Appoints Sylvain Chrétien as President
February 18, 2020
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011
February 13, 2020
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
February 13, 2020
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™
January 31, 2020
Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003
January 28, 2020
Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering
January 27, 2020
TETRA BIO-PHARMA - PRESS RELEASE CORRECTION
January 22, 2020
Tetra Bio-Pharma Announces $10.0 Million Bought Deal Offering
January 21, 2020
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs
January 20, 2020
Tetra Bio-Pharma Granted Two OTC Drug Identification Numbers (DIN) by Health Canada
January 17, 2020
Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF
January 13, 2020
Tetra Bio-Pharma Provides Update on U.S. and Canadian Regulatory Activities
December 19, 2019
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Portugal With Azevedos Indústria Farmacêutica, S.A
December 16, 2019
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug HCC011
December 10, 2019
Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma
December 4, 2019
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Mexico With Alternavida S.A.
December 2, 2019
Tetra Bio-Pharma Confirms Submission of Two OTC DIN Applications to Health Canada
November 26, 2019
FDA Approves Advancement of PPP001 Clinical Trial Previously Discontinued
November 25, 2019
Tetra Bio-Pharma Secures Financing for Hemp Energy Drink Business
November 18, 2019
Tetra Bio-Pharma Joins BIOTECanada
November 13, 2019
Tetra Bio-Pharma Confirms Regulatory Strategy of Lead Product CAUMZ™ and Strengthens Management Team
November 11, 2019
Tetra Bio-Pharma Provides Management Update on Tetra Natural Health’s Commercial Activities
October 30, 2019
Tetra Bio-Pharma Provides Management Update on Commercializing its Inhalation Drug Caumz®
October 21, 2019
Tetra Bio-Pharma Provides Regulatory Update for Its CAUMZ(TM) Kit
October 3, 2019
Tetra Bio-Pharma Announces Joint Venture with Thorne and Onegevity Health to Form CB2 Therapeutics
August 21, 2019
Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci Public Relations as Strategic Partners
August 12, 2019
Tetra's Officers and Employees Participate in Private Placement
August 3, 2019
The New Hemp Energy Drink Will Be Offered to Consumers in 700 Additional Stores in Five Provinces
July 18, 2019
Tetra Bio-Pharma’s Management Post Financing Corporate Update
July 18, 2019
The New Hemp Energy Drink Will Soon Be Available In More Than 500 Stores in Quebec
July 16, 2019
Tetra Bio-Pharma Announces Closing of Unit Offering
July 12, 2019
Panag Pharma Receives a Repayable $500,000 Contribution from the Atlantic Canada Opportunities Agency (ACOA)
July 11, 2019
Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
July 5, 2019
Tetra Bio-Pharma Inc. Announces Pricing of Unit Offering
June 24, 2019
Tetra Bio-Pharma Inc. Announces Voting Results of 2019 Annual General and Special Meeting
June 21, 2019
Tetra Bio-Pharma Inc. Announces Proposed Offering of Units
June 19, 2019
New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US
June 18, 2019
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
June 18, 2019
Tetra Bio-Pharma Inc. Announces Change of Annual General Meeting Time
June 17, 2019
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
June 17, 2019
Tetra Bio-Pharma Inc. Announces Director Resignation
June 14, 2019
Panag Pharma Completes Phase 3 Trial With Awaye™
June 11, 2019
Tetra Bio-Pharma to Present Key Research Findings as Part of Food and Drug Administration (FDA) Public Hearing on CBD
May 30, 2019
Tetra Bio-Pharma Announces the Retirement of Bernard Lessard and the Appointment of Sabino Di Paola as Chief Financial Officer
May 14, 2019
Tetra Bio-Pharma’s Recently acquired Wholly Owned Subsidiary Panag Pharma Provides an Update on Recent Activities
May 9, 2019
Tetra Bio-Pharma’s Subsidiary, Panag Pharma, Obtains Health Canada Authorization to Commence Its First Veterinary Clinical Study
May 2, 2019
Tetra Bio-Pharma Closes the Acquisition of Panag Pharma
May 1, 2019
Tetra Natural Health Announces The Arrival of 20 containers of Hemp Energy Drink in Canada
April 30, 2019